SG11201900565RA - New use of n,n-bis-2-mercaptoethyl isophthalamide - Google Patents
New use of n,n-bis-2-mercaptoethyl isophthalamideInfo
- Publication number
- SG11201900565RA SG11201900565RA SG11201900565RA SG11201900565RA SG11201900565RA SG 11201900565R A SG11201900565R A SG 11201900565RA SG 11201900565R A SG11201900565R A SG 11201900565RA SG 11201900565R A SG11201900565R A SG 11201900565RA SG 11201900565R A SG11201900565R A SG 11201900565RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- nbmi
- bis
- pct
- paracetamol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
ASTVehicle n= AST NBMI n=10 p=0.00204 ALT Vehicle n=13 ** * 952 _AMMO ALT NBM1 n=10 p=0.00006 8507 ** 753 14511 16000 14000 12000 10000 8000 6000 4000 2000 0 O O cc O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIPO I PCT onion OH oIo01101OH100IIIIImiI10111110m0IIIIII (10) International Publication Number WO 2018/025049 Al (51) International Patent Classification: A61K 45/06 (2006.01) A61K 31/167 (2006.01) A61K 31/166 (2006.01) (21) International Application Number: PCT/GB2017/052306 (22) International Filing Date: 04 August 2017 (04.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1613535.2 05 August 2016 (05.08.2016) GB (71) Applicant: EMERAMED LIMITED [IE/IE]; Trinity House, Charleston Road, Ranelagh, Dublin 6 (IE). (72) Inventors: HALEY, Boyd Eugene; 119 Burnside Drive, Nicholasville, Kentucky 40356 (US). KLINGBERG, Rag- nar Axel Theodor; Brantingsgatan 42, 115 35 Stockholm (SE). (74) Agent: MCNEENEY, Stephen Phillip; Potter Clarkson LLP, The Belgrave Centre, Talbot Street, Nottingham NG1 5GG (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: NEW USE OF N,N-BIS-2-MERCAPTOETHYL ISOPHTHALAMIDE Liver enzymes 24hrs after 200mg/kg Paracetamol i.p. w/o synchron NBMI 680 mg/kg oral dose (U/L) Figure 6 (57) : There is provided the compound N,N-bis-2-mercaptoethyl isophthalamide (NBMI), or a pharmaceuticaliy-acceptable salt and/or derivative thereof, for use in the treatment or prevention of paracetamol toxicity. Such compounds have particular utility in the treatment or prevention of acute liver failure associated with paracetamol toxicity. [Continued on next page] WO 2018/025049 Al MIDEDIMOMMIONE1011111100IIMMEHOM Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201613535 | 2016-08-05 | ||
| PCT/GB2017/052306 WO2018025049A1 (en) | 2016-08-05 | 2017-08-04 | New use of n,n-bis-2-mercaptoethyl isophthalamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900565RA true SG11201900565RA (en) | 2019-02-27 |
Family
ID=60202272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900565RA SG11201900565RA (en) | 2016-08-05 | 2017-08-04 | New use of n,n-bis-2-mercaptoethyl isophthalamide |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20190240173A1 (en) |
| EP (2) | EP3493849B1 (en) |
| JP (1) | JP6926192B2 (en) |
| KR (1) | KR102538388B1 (en) |
| CN (1) | CN109562179A (en) |
| AU (1) | AU2017305661B2 (en) |
| BR (1) | BR112019002130A2 (en) |
| CA (1) | CA3032858A1 (en) |
| CL (1) | CL2019000229A1 (en) |
| CY (1) | CY1125039T1 (en) |
| DK (1) | DK3493849T3 (en) |
| EA (1) | EA201990443A1 (en) |
| ES (1) | ES2907838T3 (en) |
| HR (1) | HRP20220252T1 (en) |
| HU (1) | HUE057782T2 (en) |
| IL (1) | IL264538B2 (en) |
| LT (1) | LT3493849T (en) |
| MA (1) | MA45855B1 (en) |
| MD (1) | MD3493849T2 (en) |
| MX (1) | MX2019000978A (en) |
| PH (1) | PH12019500237A1 (en) |
| PL (1) | PL3493849T3 (en) |
| PT (1) | PT3493849T (en) |
| RS (1) | RS62924B1 (en) |
| SG (1) | SG11201900565RA (en) |
| SI (1) | SI3493849T1 (en) |
| UA (1) | UA125394C2 (en) |
| WO (1) | WO2018025049A1 (en) |
| ZA (1) | ZA201900594B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005057D0 (en) | 2020-04-06 | 2020-05-20 | Emeramed Ltd | New Use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6586600B2 (en) | 2000-12-06 | 2003-07-01 | University Of Kentucky Research Foundation | Multidentate sulfur-containing ligands |
| US8950583B2 (en) * | 2008-12-06 | 2015-02-10 | Ermes Medical Company Limited | Method to remove heavy metals from a mammal |
| WO2011006097A2 (en) * | 2009-07-10 | 2011-01-13 | The Brigham And Women's Hospital, Inc. | Methods For Treating Toxicity |
| WO2011038385A2 (en) | 2009-09-28 | 2011-03-31 | University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from contaminated milieu and methods of use |
| US8575218B2 (en) | 2009-09-28 | 2013-11-05 | The University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| US20110237776A1 (en) | 2010-03-25 | 2011-09-29 | Haley Boyd E | Aromatic compounds with sulfur containing ligands |
| US8426368B2 (en) | 2010-03-25 | 2013-04-23 | The University Of Kentucky Research Foundation | Method of ameliorating oxidative stress and supplementing the diet |
-
2017
- 2017-08-04 MA MA45855A patent/MA45855B1/en unknown
- 2017-08-04 HU HUE17793720A patent/HUE057782T2/en unknown
- 2017-08-04 EA EA201990443A patent/EA201990443A1/en unknown
- 2017-08-04 PL PL17793720T patent/PL3493849T3/en unknown
- 2017-08-04 RS RS20220147A patent/RS62924B1/en unknown
- 2017-08-04 LT LTEPPCT/GB2017/052306T patent/LT3493849T/en unknown
- 2017-08-04 CN CN201780046065.1A patent/CN109562179A/en active Pending
- 2017-08-04 UA UAA201902172A patent/UA125394C2/en unknown
- 2017-08-04 BR BR112019002130-2A patent/BR112019002130A2/en active Search and Examination
- 2017-08-04 MD MDE20190671T patent/MD3493849T2/en unknown
- 2017-08-04 AU AU2017305661A patent/AU2017305661B2/en active Active
- 2017-08-04 SG SG11201900565RA patent/SG11201900565RA/en unknown
- 2017-08-04 WO PCT/GB2017/052306 patent/WO2018025049A1/en active Search and Examination
- 2017-08-04 EP EP17793720.8A patent/EP3493849B1/en active Active
- 2017-08-04 MX MX2019000978A patent/MX2019000978A/en unknown
- 2017-08-04 DK DK17793720.8T patent/DK3493849T3/en active
- 2017-08-04 JP JP2019505490A patent/JP6926192B2/en active Active
- 2017-08-04 KR KR1020197003227A patent/KR102538388B1/en active IP Right Grant
- 2017-08-04 CA CA3032858A patent/CA3032858A1/en active Pending
- 2017-08-04 EP EP21211493.8A patent/EP4029497A1/en not_active Withdrawn
- 2017-08-04 ES ES17793720T patent/ES2907838T3/en active Active
- 2017-08-04 SI SI201731094T patent/SI3493849T1/en unknown
- 2017-08-04 HR HRP20220252TT patent/HRP20220252T1/en unknown
- 2017-08-04 PT PT177937208T patent/PT3493849T/en unknown
- 2017-08-04 US US16/318,842 patent/US20190240173A1/en not_active Abandoned
-
2019
- 2019-01-28 ZA ZA2019/00594A patent/ZA201900594B/en unknown
- 2019-01-29 CL CL2019000229A patent/CL2019000229A1/en unknown
- 2019-01-29 IL IL264538A patent/IL264538B2/en unknown
- 2019-02-01 PH PH12019500237A patent/PH12019500237A1/en unknown
-
2022
- 2022-03-01 CY CY20221100175T patent/CY1125039T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201909837YA (en) | Methods for treating lung disorders |